Table 2 Patient demographics of the enrolled CHC and NAFLD patient groups in the study.
CHC (n = 36) | NAFLD (n = 41) | Statistics between groups* p value < 0.05 | ||
|---|---|---|---|---|
Steatosis grade = 1 | Steatosis grade ≧ 2 | |||
Gender (F/M) | 24/12 | 13/17 | 4/7 | |
Age (years) | 66 (46–81) | 50 (25–85) | 54 (27–72) | a, b |
BMI (kg/m2) | 24.8 (18.7–34.8) | 25.3 (21.1–32.5) | 27.8 (24.1–36.7) | b, c |
Body fat (%) | 35.7 (20.7–51.7) | 29.2 (18.4–44.1) | 33.8 (20.6–44.6) | a |
GOT (U/L) | 56 (23–346) | 21 (15–113) | 26 (15–95) | a, b |
GPT (U/L) | 74 (19–349) | 27 (13–118) | 46 (15–177) | a, b, c |
TC (mg/dL) | 167 (108–259) | 198 (149–312) | 217 (136–256) | a, b |
TG (mg/dL) | 85 (36–176) | 127 (30–338) | 166 (49–513) | a, b |
LDL (mg/dL) | 95 (55–181) | 120 (78–240) | 149 (82–172) | a, b |
HDL (mg/dL) | 59 (26–90) | 51 (30–74) | 49 (26–77) | a |
HbA1c (%) | 5.4 (4.7–5.9) | 5.7 (4.2–5.9) | 5.6 (5.1–5.9) | a, b |
Plasma apoJ (mg/dL) | 17.4 (11.8–22.0) | 22.5 (15.8–26.8) | 22.1 (20.6–24.9) | a, b |
HCV RNA (Log10 IU/mL) | 6.0 (2.6–6.9) | Not detectable | Not detectable | |
